Bionime (TPE:4737) Accounts Payable: NT$142 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4737 Bionime Corp TPE:4737
65 GF Score
Price NT$55.30
GF Value NT$58.72
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Accounts Payable?

Bionime TPE:4737 +0.91% 65 Accounts Payable is NT$142 Mil as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.72 (Fairly Valued). The stock has 7 warning signs investors should review.

Bionime's Accounts Payable for the quarter that ended in Dec. 2025 was NT$142 Mil.

Bionime's quarterly Accounts Payable declined from Jun. 2025 (NT$148 Mil) to Sep. 2025 (NT$142 Mil) and declined from Sep. 2025 (NT$142 Mil) to Dec. 2025 (NT$142 Mil).

Bionime's annual Accounts Payable increased from Dec. 2023 (NT$148 Mil) to Dec. 2024 (NT$191 Mil) but then declined from Dec. 2024 (NT$191 Mil) to Dec. 2025 (NT$142 Mil).

Bionime Accounts Payable Historical Data

* Premium members only.

The historical data trend for Bionime's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Accounts Payable Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 151.13 179.19 147.69 191.41 141.64

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 191.41 174.32 147.74 141.90 141.64
TPE:4737
65GF Score
Bionime Corp TPE:4737
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$142 Mil mean?
Bionime (TPE:4737) has a Accounts Payable of NT$142 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Bionime and its competitors.
Is Bionime's Accounts Payable too high?
Bionime's current Accounts Payable is NT$142 Mil. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Accounts Payable compare to ISRG and BDX?
Bionime's Accounts Payable of NT$142 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Bionime and its competitors. Bionime's current Accounts Payable is NT$142 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.72, compared to a current price of NT$55.30 — trading 5.8% below its estimated fair value. The current Accounts Payable is NT$142 Mil. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Bionime (TPE:4737), the current Accounts Payable is NT$142 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$55.30 is trading 5.8% below its estimated GF Value™ of NT$58.72. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Accounts Payable: NT$142 Mil
  • GF Value™: NT$58.72 vs. price of NT$55.30 (5.8% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score

Get the complete analysis for TPE:4737

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$55.30
Price
NT$58.72
GF Value